Research brief · 2026-09-09
How to Read ClinicalTrials.gov
ClinicalTrials.gov exists so that anyone can find out that a study was registered, what it planned to measure and, ideally, what it found. Registration is largely a formality: a sponsor submits a title, a design and planned outcomes before or shortly after the trial starts. None of that requires the trial to finish or ever report back. Five fields do most of the interpretive work: status, primary completion date, whether results have been posted, the sponsor, and enrollment.
Status is the most load-bearing field. Recruiting means nothing to report yet. Completed means the trial ran its course. Terminated means it stopped partway. NCT00267527, a Phase 2 trial of CJC-1295, an unapproved peptide, in HIV-associated visceral obesity, planned 120 people and is listed as Terminated in 2006 with no stated reason and no results. Unknown means the completion date passed and the sponsor never updated the record. NCT02637284, the only genuine human trial of BPC-157, enrolled 42 healthy volunteers in 2015, finished in 2016, and has shown Unknown status ever since, with no results.
The bigger trap is a trial that reaches Completed and still reports nothing. NCT01280344 tested ipamorelin, an unapproved growth hormone secretagogue, for gut recovery after bowel surgery in 320 people across 45 locations, sponsored by Helsinn Therapeutics. It reached Completed in 2014, and the results field shows nothing has ever been posted. For contrast, NCT03548935, the STEP 1 trial of semaglutide, a prescription medication, enrolled 1,961 adults, sponsored by Novo Nordisk, completed on schedule and shows posted results. Large sponsors with an approval riding on the outcome are where the system tends to work.
A practical reading order: status, then completion date against today, then the separate results-posted field, then sponsor, then planned versus actual enrollment. What the registry cannot tell you is why a trial went quiet, or whether data exists somewhere a sponsor never filed. It shows that a record is silent, not what the silence means. Sources are listed below.
Sources
- ClinicalTrials.gov NCT02637284, Phase 1 safety and pharmacokinetics of PCO-02 (BPC-157), n=42, status Unknown, no results
- ClinicalTrials.gov, 2015
- ClinicalTrials.gov NCT01280344, Phase 2 ipamorelin for recovery of gastrointestinal function after bowel resection, n=320, Completed, no results
- ClinicalTrials.gov, 2011
- ClinicalTrials.gov NCT00267527, Phase 2 CJC-1295 in HIV-associated visceral obesity, n=120, Terminated, no results
- ClinicalTrials.gov, 2005
- ClinicalTrials.gov NCT03548935, STEP 1 trial of semaglutide in overweight or obesity, sponsor Novo Nordisk, n=1,961, Completed, results posted
- ClinicalTrials.gov, 2018
Peptide Proof reports what studies found. We do not give medical advice, dosing guidance, or treatment recommendations.